Metaclazepam

Metaclazepam, marketed under the brand name Talis, belongs to the class of drugs known as benzodiazepine derivatives. Specifically, it is identified as a relatively selective anxiolytic, which implies it primarily counteracts anxiety without producing significant sedative or muscle-relaxant effects commonly associated with other benzodiazepines.

Pharmacology

Metaclazepam undergoes metabolic processes in the body to produce its primary active metabolite, N-desmethylmetaclazepam. There has been no observed significant difference in the metabolism of metaclazepam between younger and older individuals, suggesting age doesn't considerably alter its pharmacokinetic profile.

Therapeutic Efficacy

Compared to other benzodiazepines such as bromazepam and diazepam, metaclazepam displays slightly enhanced efficacy as an anxiolytic. In terms of dose equivalency, a 15 mg dose of metaclazepam is analogous to a 4 mg dose of bromazepam.

Drug Interactions

When combined with alcohol, metaclazepam may exhibit additive sedative-hypnotic effects. This interaction is a crucial consideration for patients and clinicians, as the co-ingestion could elevate the risk of overdose or lead to impaired cognition and motor functions.

Side Effects

Fatigue is a frequently reported side effect when consuming high doses of metaclazepam. Other potential side effects might include drowsiness, dizziness, and impaired coordination.

Special Considerations

Breastfeeding mothers should exercise caution as metaclazepam and its metabolites have been detected in human breast milk, potentially posing a risk to nursing infants.

See Also

• Benzodiazepines
• Anxiolytic drugs
• Pharmacokinetics

‎